BOCA RATON, FL--(Marketwire - August 19, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Drs. Daniel Weiss and Jerry Anchin, Vicor's Chief Medical Officer and Director of Research and Development, respectively, participated in the start of a new cardiac screening initiative being conducted by Cardiac Risk in the Young (CRY), a London-based non-profit organization. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
Specifically, Drs. Weiss and Anchin trained technicians in the use of the Company's PD2i® nonlinear algorithm and supervised initial data collection efforts. Approximately 30 14 year olds were tested with the PD2i® nonlinear algorithm. The multi-year CRY initiative will offer free cardiac screening to 14 year olds (DOB 1995); 14 is the earliest post-puberty age for which proactive screening is considered valuable. Participants will then be tested annually through age 19. In addition to identifying those youngsters who are at elevated risk of sudden cardiac death for referral for further evaluation, a goal of the study is to assess the changes that occur in those risk factors through the teenage years. Approximately 600 young people are struck down by sudden cardiac death annually in the U.K. Ten percent of the estimated seven million individuals fitting this description are expected to participate.
Dr. Sanjay Sharma, the consulting cardiologist spearheading the initiative, selected Vicor's PD2i® nonlinear algorithm for use in the CRY screening initiative. The ultimate goal of the screening initiative is to improve the accuracy of identifying teenagers at elevated risk of sudden cardiac death in the future.
"We're delighted by the level of enthusiasm the CRY staff showed for the PD2i®. Initially, the technicians were hesitant about including the PD2i® test in their screening regimen because they were unfamiliar with it. Once they discovered how easy to use it is -- by lunch time of the first day -- they were very excited to be using the PD2i®, a tool that, they said, adds tremendous value to their efforts by enabling a risk prognostic. The CRY screening initiative is an incredibly well-organized and professionally-run operation. No doubt it will be a great success in furthering understanding of cardiac death in the young," stated Dr. Anchin.
The CRY screening initiative takes place two weekends per month at the Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George's Healthcare NHS Trust. Azra Loncarevic-Srmic, project manager, oversees three ECG technicians, an echocardiogram technician, a resident cardiologist, and two schedulers. According to Ms. Loncarevic-Srmic, they anticipate screening 300 participants per weekend.
"We're honored to have our PD2i® nonlinear algorithm selected for use in this important initiative. Given the consistently accurate results achieved, to date, with the PD2i® nonlinear algorithm in risk stratifying adults at risk of sudden cardiac death, we're confident that the PD2i® nonlinear algorithm will prove beneficial in identifying youths in need of treatment to prevent a cardiac episode," stated Mr. Fater.
Dr. Sharma is Professor of the recently-created Inherited Cardiovascular Disease and Sports Cardiology Centre at St. George's Healthcare NHS Trust. The Inherited Cardiovascular Disease and Sports Cardiology Centre is the world's first specialist, multi-disciplinary facility dedicated to providing services to populations -- those between the ages of 14 and 35, including families and athletes -- affected by or at risk for sudden cardiac death. St. George's is one of England's largest teaching hospitals and the first hospital in the United Kingdom to develop a specialist clinic for young sudden cardiac death after receiving CRY's donation of echocardiogram equipment. CRY was founded in 1996 to raise awareness of conditions that can lead to sudden cardiac death and sudden cardiac death syndrome in those between the ages of 14 and 35. Additional information about CRY may be found at http://www.c-r-y.org.uk/.
About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.
The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.
Vicor anticipates developing additional applications utilizing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Institute for Surgical Research, the Department of the Army, Department of Defense, the U.S. Government, or CRY of the information, products or services contained therein.
Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.